Rx/Reimbursement Adult Incontinence in Australia

Rx/Reimbursement Adult Incontinence in Australia

The Continence Aids Payment Scheme Amendment (Eligibility) Instrument 2022 changed who can get payments under the Continence Aids Payment Scheme (CAPS) to avoid double-dipping. It means that care recipients who already receive continence products as part of a residential care service are not eligible for additional payments under the CAPS.

Euromonitor International's Rx/Reimbursement adult incontinence in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2027 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Rx/Reimbursement adult incontinence market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.